EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

4-Octyl Itaconate Against Septic Cardiac Injury by Suppressing Cardiac Lymphatic Vessel Inflammation via the RhoA-ROCK1 Signaling Pathway

Haoran Wu iD, Xin Zhang, Xinglin Wang, Yu Ma, Ping Yang, Yang Liu, Liyun Li, Qiuting Li, Linyi Tang, Jinwei Pang iD, Rong Li iD, Chunxiang Zhang iD

Clinical Science · 2026

DOI: 10.1042/cs20258569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Science, 2026. Verfasst von Haoran Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Key Laboratory of Medical Electrophysiology, Ministry of Education…. Hauptthemen laut MEDLINE: rho-Associated Kinases, Sepsis, rhoA GTP-Binding Protein, Succinates. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Sichuan Science and Technology Program, Luzhou Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sepsis-associated cardiac injury represents a significant complication of critical infections, leading to cardiac dysfunction, myocardial oedema and myocardial inflammation. These manifestations result in severe target organ damage with an unfavourable prognosis and an elevated risk of mortality. The clearance of inflammatory immune cells infiltrating the heart and the attenuation of myocardial oedema are key functions of the cardiac lymphatic system. This study investigates the protective effects of 4-OI (4-octyl itaconate) against LPS-mediated cardiac injury in a mouse model. We established acute cardiac dysfunction through intraperitoneal LPS injection and assessed cardiac function via small-animal ultrasound. Results indicated that LPS significantly impaired cardiac function, evidenced by decreased left ventricular ejection fraction (EF%) and fractional shortening (FS%). Treatment with 4-OI improved these parameters and reduced serum markers of myocardial injury, including cTnT and LDH. Additionally, 4-OI mitigated LPS-induced cardiac edema and vascular leakage, as demonstrated by Evans Blue dye assays. Histological analyses revealed that 4-OI reduced inflammatory cell infiltration, particularly M1-type macrophages, and stabilized cardiac lymphatic endothelial function. To further elucidate the mechanism, we blocked lymphatic reflux via thoracic duct ligation, which diminished the therapeutic efficacy of 4-OI, indicating the involvement of cardiac lymphatics in its protective effects. Furthermore, in vitro studies showed that 4-OI reduced inflammatory responses in lymphatic endothelial cells (LECs) and stabilized intercellular junctions disrupted by LPS. Network pharmacological analysis identified RhoA/ROCK1 signaling as a potential target of 4-OI in treating LPS-induced endothelial dysfunction. In conclusion, 4-OI exhibits significant cardioprotective effects against LPS-induced acute cardiac dysfunction, primarily through modulation of inflammatory responses and stabilization of lymphatic endothelial function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

rho-Associated KinasesSepsisrhoA GTP-Binding ProteinSuccinatesLymphatic Vesselsrho GTP-Binding ProteinsAnti-Inflammatory AgentsAnimalsSignal TransductionLipopolysaccharidesMaleMice, Inbred C57BLDisease Models, AnimalMiceMyocardium

Stichwörter der Autor:innen

Itaconic acidRhoA/ROCK1Sepsiscardiac lymphaticslipopolysaccharide

Substanzen

rho-Associated KinasesrhoA GTP-Binding ProteinSuccinatesLipopolysaccharidesRhoA protein, mouserho GTP-Binding ProteinsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Key Laboratory of Medical Electrophysiology, Ministry of Education, Institute of Cardiovascular Research, Basic Medicine Research Innova…
  • School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China.
  • Department of Pharmacy, The Third People's Hospital of Yibin, Sichuan, China.
  • Department of Rehabilitation Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, China.
  • Southwest Medical University, Department of Neurosurgery, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
  • Basic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education, Luzhou Municipal Key Laboratory of Thrombosis and Vascular Biology, Laboratory for Cardiovascular Pharmacology, Department o…

ORCID-Profile: Haoran Wu, Jinwei Pang, Rong Li, Chunxiang Zhang

Förderung

  • National Natural Science Foundation of China
  • Sichuan Science and Technology Program
  • Luzhou Science and Technology Project
  • Research Start-up Foundation of Southwest Medical University
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • 2025 Annual Commission-University Joint Innovation Fund Project of Chengdu Municipal Health Commission and Chengdu University of Traditional Chinese Medicine

Zitieren

APA

Wu, H., Zhang, X., Wang, X., Ma, Y., Yang, P., Liu, Y., Li, L., Li, Q., Tang, L., Pang, J., Li, R., & Zhang, C. (2026). 4-Octyl Itaconate Against Septic Cardiac Injury by Suppressing Cardiac Lymphatic Vessel Inflammation via the RhoA-ROCK1 Signaling Pathway. Clinical Science. https://doi.org/10.1042/cs20258569

Vancouver

Wu H, Zhang X, Wang X, Ma Y, Yang P, Liu Y, et al. 4-Octyl Itaconate Against Septic Cardiac Injury by Suppressing Cardiac Lymphatic Vessel Inflammation via the RhoA-ROCK1 Signaling Pathway. Clinical Science. 2026. doi:10.1042/cs20258569

BibTeX
@article{Wu2026,
  author = {Wu, Haoran and Zhang, Xin and Wang, Xinglin and Ma, Yu and Yang, Ping and Liu, Yang and Li, Liyun and Li, Qiuting and Tang, Linyi and Pang, Jinwei and Li, Rong and Zhang, Chunxiang},
  title = {4-Octyl Itaconate Against Septic Cardiac Injury by Suppressing Cardiac Lymphatic Vessel Inflammation via the RhoA-ROCK1 Signaling Pathway},
  journal = {Clinical Science},
  year = {2026},
  doi = {10.1042/cs20258569}
}
Kostenlos starten →